articleTop 1% cited

Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an <scp>EAACI</scp> Position Paper

Allergy · 2014 · Vol. 69(7) · pp. 854–867

Oliver Pfaar✉(Heidelberg University)Pascal Demoly(Sorbonne Université)Roy Gerth van Wijk(Erasmus MC)С. Бонини(Istituto di Farmacologia Traslazionale)Jean Bousquet(Inserm)Giorgio Walter Canonica(Ospedale Policlinico San Martino)Stephen R. Durham(Lung Institute)Lars JacobsenHans‐Jørgen Malling(Gentofte Hospital)Ralph Mösges(University of Cologne)Nikolaos G. Papadopoulos(National and Kapodistrian University of Athens)S. Rak(Sahlgrenska University Hospital)Pablo Rodríguez del Río(Hospital Infantil Universitario Niño Jesús)Erkka Valovirta(University of Turku)Ulrich Wahn(Charité - Universitätsmedizin Berlin)Moisés A. Calderón(Lung Institute)

View via DOI Publisher page

Abstract

A standardized and globally harmonized method for analysing the clinical efficacy of AIT products in RCTs is required. The EAACI TF highlights the CSMS as the primary endpoint for future RCTs in AIT for allergic rhinoconjunctivitis.

Allergic Rhinitis and Sensitization Asthma and respiratory diseases Dermatology and Skin DiseasesMedicineAllergen immunotherapyClinical endpointClinical trialAllergyRandomized controlled trialPosition paperImmunotherapyAsthmaIntensive care medicine